(Q51782188)

12 April 2018

review article

1 reference

title

New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone. (English)

1 reference

12 April 2018

1 reference

amiodarone

15 June 2024

R W Kreeger

1

1 reference

12 April 2018

S C Hammill

series ordinal

2

1 reference

12 April 2018

language of work or name

English

0 references

publication date

1 November 1987

1 reference

12 April 2018

published in

Mayo Clin Proc

1 reference

12 April 2018

volume

62

1 reference

12 April 2018

issue

11

1 reference

12 April 2018

page(s)

1033-1050

1 reference

12 April 2018

New antiarrhythmic drugs: their place in therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Aggravation of ventricular arrhythmia. A drug-induced complication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Antiarrhythmic drug classification: new science and practical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

A Classification of Antiarrhythmic Actions Reassessed After a Decade of New Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Flecainide: a new antiarrhythmic agent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

New perspectives in the pharmacologic therapy of cardiac arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Clinical pharmacokinetics of the newer antiarrhythmic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Antiarrhythmic drug action. Blockade of the inward sodium current

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Clinical types of proarrhythmic response to antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Tocainide: a new oral antiarrhythmic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic, tocainide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Open clinical studies at a referral center: chronic maintenance tocainide therapy in patients with recurrent sustained ventricular tachycardia refractory to conventional antiarrhythmic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Short- and long-term therapy with tocainide for malignant ventricular tachyarrhythmias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Clinical electrophysiologic effects of tocainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Tocainide for drug-resistant ventricular arrhythmias: efficacy, side effects, and lidocaine responsiveness for predicting tocainide success.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Tocainide. A review of its pharmacological properties and therapeutic efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Clinical profiles of newer class I antiarrhythmic agents--tocainide, mexiletine, encainide, flecainide and lorcainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Tocainide: a new oral antiarrhythmic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Aplastic anemia due to tocainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

7 January 2021

Drug therapy. Tocainide

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

The effect of Kö 1173, a new anticonvulsant agent on experimental cardiac arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Pharmacology, electrophysiology, and pharmacokinetics of mexiletine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Mexiletine for control of drug-resistant ventricular tachycardia: Clinical and electrophysiologic results in 44 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Oral mexiletine in the treatment of refractory ventricular arrhythmias: The role of electrophysiologic techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Mexiletine for refractory-ventricular arrhythmias: results using serial electrophysiologic testing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Long-term mexiletine for ventricular arrhythmia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

The interaction of mexiletine with other cardiovascular drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Combined mexiletine and amiodarone treatment of refractory recurrent ventricular tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Efficacy of combination therapy with mexiletine and a type IA agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Intolerance and ineffectiveness of mexiletine in patients with serious ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Practical considerations in the treatment of ventricular arrhythmias with mexiletine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Hemodynamic effects of mexiletine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Lack of effectiveness of oral mexiletine in patients with drug-refractory paroxysmal sustained ventricular tachycardia. A study utilizing programmed stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Mexiletine for ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Discovery and development of flecainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Antiarrhythmics. 2. Synthesis and antiarrhythmic activity of N-(piperidylalkyl)trifluoroethoxybenzamides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

7 January 2021

Metabolism of flecainide

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

7 January 2021

Drug therapy. Flecainide

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Conversion of supraventricular arrhythmias to sinus rhythm using flecainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Evaluation of flecainide acetate in the management of patients at high risk of sudden cardiac death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Flecainide in the treatment of nonsustained ventricular tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Oral flecainide acetate for the treatment of ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Flecainide versus quinidine: Results of a multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

A double-blind, crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Treatment of resistant ventricular tachycardia with flecainide acetate. Flecainide Ventricular Tachycardia Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Electrophysiologic and antiarrhythmic effects of oral flecainide in patients with inducible ventricular tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Electrophysiologic properties of flecainide acetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Effects of flecainide on ventricular function: clinical and experimental correlations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Clinical and electrophysiologic assessment of oral flecainide acetate for recurrent ventricular tachycardia: evidence for exacerbation of electrical instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Extracardiac adverse effects of flecainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

The effect of flecainide acetate, a new antiarrhythmic, on plasma digoxin levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Basic and clinical cardiac electrophysiology of encainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Electrophysiology of oral encainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Acute intravenous and long-term oral hemodynamic effects of encainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Treatment of supraventricular arrhythmias with encainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Encainide for treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Electrophysiologic and clinical effects of intravenous and oral encainide in accessory atrioventricular pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Suppression of incessant supraventricular tachycardia by intravenous and oral encainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Encainide for refractory supraventricular tachycardia in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Treatment of frequent ventricular arrhythmia with encainide: assessment using serial ambulatory electrocardiograms, intracardiac electrophysiologic studies, treadmill exercise tests, and radionuclide cineangiographic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Dosing recommendations for encainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Encainide for ventricular arrhythmias: placebo-controlled and standard comparison trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Encainide in lethal ventricular arrhythmias evaluated by electrophysiologic testing and decrease in symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Safety and efficacy of encainide for malignant ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Electrophysiology, hemodynamic and arrhythmia efficacy model studies on encainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Relation of blood level and metabolites to the antiarrhythmic effectiveness of encainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Disposition kinetics of encainide and metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Drug interaction studies and encainide use in renal and hepatic impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Electrophysiology in assessing supraventricular arrhythmias: value of programmed stimulation in predicting and understanding efficacy of encainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Safety of encainide for the treatment of ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Effects of encainide and its metabolites on energy requirements for defibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Amiodarone: Historical development and pharmacologic profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Amiodarone for Tachyarrhythmias: Pharmacology, Kinetics, and Efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Clinical pharmacology and therapeutic applications of the antiarrhythmic agent amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Clinical efficacy of amiodarone as an antiarrhythmic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Prognosis after sudden cardiac death without associated myocardial infarction: one year follow-up of empiric therapy with amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Amiodarone: intravenous loading for rapid suppression of complex ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Effect of amiodarone in paroxysmal supraventricular tachycardia with or without Wolff-Parkinson-White syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Amiodarone in refractory life-threatening ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Amiodarone for refractory atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Amiodarone for long-term management of patients with hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Rhythm disturbances in hypertrophic cardiomyopathy: prevalence, relation to symptoms and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Effect of amiodarone on left ventricular ejection and filling in hypertrophic cardiomyopathy as assessed by radionuclide angiography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue drug concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Amiodarone. Biochemical aspects and haemodynamic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Important differences between short- and long-term hemodynamic effects of amiodarone in patients with chronic ischemic heart disease at rest and during ischemia-induced left ventricular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Transient exacerbation followed by control of ventricular tachycardia with amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Side effects and complications of amiodarone therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Amiodarone pulmonary toxicity. Assessment by bronchoalveolar lavage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Rapid suppression of complex ventricular arrhythmias with high-dose oral amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Evaluation by serial electrophysiologic studies of an abbreviated oral loading regimen of amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Multicenter controlled observation of a low-dose regimen of amiodarone for treatment of severe ventricular arrhythmias. Collaborative Group for Amiodarone Evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Clinical intracardiac electrophysiologic testing: technique, diagnostic indications, and therapeutic uses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

Flecainide: a new class Ic antidysrhythmic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

inferred from DOI database lookup

7 January 2021

based on heuristic

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965077-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-6196(12)65077-0

1 reference

12 April 2018

1 reference

12 April 2018